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Abstract
Background: Increased levels of inflammation have been associated with a poorer response to antidepressants in several 
clinical samples, but these findings have had been limited by low reproducibility of biomarker assays across laboratories, 
difficulty in predicting response probability on an individual basis, and unclear molecular mechanisms.
Methods: Here we measured absolute mRNA values (a reliable quantitation of number of molecules) of Macrophage Migration 
Inhibitory Factor and interleukin-1β in a previously published sample from a randomized controlled trial comparing escitalopram 
vs nortriptyline (GENDEP) as well as in an independent, naturalistic replication sample. We then used linear discriminant 
analysis to calculate mRNA values cutoffs that best discriminated between responders and nonresponders after 12 weeks of 
antidepressants. As Macrophage Migration Inhibitory Factor and interleukin-1β might be involved in different pathways, we 
constructed a protein-protein interaction network by the Search Tool for the Retrieval of Interacting Genes/Proteins.
Results: We identified cutoff values for the absolute mRNA measures that accurately predicted response probability on 
an individual basis, with positive predictive values and specificity for nonresponders of 100% in both samples (negative 
predictive value = 82% to 85%, sensitivity = 52% to 61%). Using network analysis, we identified different clusters of targets 
for these 2 cytokines, with Macrophage Migration Inhibitory Factor interacting predominantly with pathways involved in 
neurogenesis, neuroplasticity, and cell proliferation, and interleukin-1β interacting predominantly with pathways involved in 
the inflammasome complex, oxidative stress, and neurodegeneration.
Significance Statement Box Sample
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Conclusion: We believe that these data provide a clinically suitable approach to the personalization of antidepressant 
therapy: patients who have absolute mRNA values above the suggested cutoffs could be directed toward earlier access to 
more assertive antidepressant strategies, including the addition of other antidepressants or antiinflammatory drugs.
Keywords: cytokine absolute blood levels, treatment response, predictors, personalized medicine
Introduction
While there is evidence that patients with high peripheral 
inflammation tend to respond less to conventional antidepres-
sants, we lack biomarkers that are reproducible across labora-
tories, predict response probability on an individual basis, and 
have clear molecular mechanisms underlying their predic-
tive effect. The identification of biomarkers that predict treat-
ment response is crucial in reducing the social and economic 
burden of depression and improving quality of life of patients. 
Indeed, more than one-half of patients fail to show an adequate 
response to first-line antidepressants (Trivedi, 2006), and one-
third of patients are resistant to all available pharmacological 
treatments (Rush et al., 2003); therefore, there is a need to estab-
lish personalized treatment protocols that can accelerate the 
escalation toward adjuvant pharmacological strategies in those 
deemed less likely to respond. The notion of using peripheral 
inflammation to personalize treatment in depression is sup-
ported by a recent randomized controlled trial with the tumor 
necrosis factor (TNF)-α antagonist, infliximab, providing some 
evidence that patients with high levels of inflammation are 
more likely to respond to an adjuvant treatment with antiin-
flammatory drugs (Raison et al., 2013).
Baseline concentrations of inflammatory markers, like C 
Reactive Protein (CRP) and circulating cytokines, have been pro-
posed as useful biomarkers for the identification of patients that 
will fail to respond to antidepressants. While depressed patients 
in general tend to show higher blood levels of inflammatory bio-
markers compared with controls (Howren et al., 2009;Martinez 
et  al., 2012), depressed patients who are resistant to conven-
tional antidepressants tend to have even higher concentrations 
of these biomarkers, both as plasma/serum proteins (Sluzewska 
et  al., 1997; Lanquillon et  al., 2000; Fitzgerald et  al., 2006; 
Rethorst et al., 2013) and as blood mRNA levels (Carvalho et al., 
2013; Cattaneo et al., 2013; Lisi et al., 2013; Powell et al., 2013). 
However, despite this large amount of evidence, none of these 
findings have been translated yet into clinical practice, partly 
because different studies use different biomarkers, often meas-
ured with assays that are laboratory specific. Moreover, these 
assays have relative rather than absolute validity: that is, they 
can separate 2 groups defined as responders/nonresponders but 
do not necessarily predict the response probability on an indi-
vidual basis. The recent study using CRP to predict differential 
response to nortriptyline vs escitalopram is an important step 
forward, because CRP is a commonly available and standardized 
test, but it lacks the molecular insight, since CRP is the final out-
come of a number of inflammatory pathways (Uher et al., 2014).
Here we propose that the absolute values of Macrophage 
Migration Inhibitory Factor (MIF) and interleukin (IL)-1β blood 
mRNA molecules can be used to accurately predict antidepres-
sant treatment response across different laboratories, because 
absolute mRNA values are more likely to be comparable indepen-
dently from the laboratory setting because of the use of stand-
ard quantitation. In this study, we build on our previous work in 
the Genome-Based Therapeutic Drugs for Depression (GENDEP) 
sample, a part-randomized study with 2 active pharmacological 
treatment arms with nortriptyline vs escitalopram, which 
has been extensively described before (Uher et al., 2009, 2010; 
Keers et al., 2010). In our previous report (Cattaneo et al., 2013), 
we measured the blood mRNA relative expression levels of 
cytokines, that is, we normalized the levels of each cytokine vs 
the levels of internal controls (housekeeping genes). Of the many 
cytokines assessed (IL1α, IL-1β, IL-4, IL-6, IL-7, IL-8, IL-10, MIF, 
and TNF-α), only the 3 proinflammatory cytokines, IL-1β, MIF, 
and TNF-α, were higher in patients who later did not respond 
to antidepressants compared with those who did. In the pre-
sent paper, we aim to: (1) select the strongest predictors (among 
the 3 cytokines) using multivariate logistic regression model; (2) 
identify the absolute mRNA values (number of molecules) cut-
offs that best allocate individuals to the responders and nonre-
sponders classes; (3) validate the same absolute mRNA values 
cutoffs in an independent sample recruited in a naturalistic 
setting; and (4) conduct a network analyses to assess the main 
targets of these proinflammatory cytokines, thus contributing to 
mechanistic understanding.
Materials and Methods
Study Design and Sample
GENDEP Study
The GENDEP project is an open-label, part-randomized, mul-
ticenter pharmacogenetic study with 2 active pharmacologi-
cal treatment arms that has been extensively described before 
(Uher et  al., 2009, 2014; Keers et  al., 2010; Powell et  al., 2012; 
Cattaneo et al., 2013). For the main study, 811 adults with uni-
polar major depression of at least moderate severity according 
to both the ICD–10 (World Health Organization, 1992)  and the 
DSM–IV (American Psychiatric Association, 1994) were recruited 
and randomly allocated to receive flexible dosage of nortrip-
tyline (50–150 mg daily) or escitalopram (10–30 mg daily) for 12 
weeks. Other psychotropic medications were not allowed, with 
the exception of occasional use of hypnotics. Response to anti-
depressant medication was quantified as percentage reduction 
in the Montgomery–Åsberg Depression Rating Scale (MADRS) 
score from baseline to week 12, and responders were identified 
as patients with a reduction in MADRS > 50%; according to this 
definition, approximately 55% of patients in this sample were 
classified as responders (Uher et  al., 2009). Written informed 
consent was obtained from all participants, and the study was 
approved by the local ethics committee.
For the present study, we selected all patients who had been 
drug free for at least 2 weeks before entering into the trial and 
provided a baseline blood PaxGene tube for mRNA gene expres-
sion analysis (n = 74). On average, they were in their second epi-
sode of moderately severe depression and scored, at baseline, 
28.7 (± 4.2) on the MADRS; according to the percent change in 
the MADRS score, 69% (51 of 74)  were defined as responders 
(the selective inclusion of drug free patients may have led to a 
slightly more antidepressant-responsive group compared with 
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the total sample). The main demographic and clinical features 
are summarized in Table 1. There were no significant differences 
between patients treated with escitalopram (n = 38) or nortryp-
tiline (n = 36) in age (38 ± 12.4 vs 36 ± 9.4, P = .25), gender (F/M was 
20/18 vs 23/13, P = .2), or response rate (responders/nonrespond-
ers were 26/12 vs 25/11, P = .6).
Validation Sample
A second independent sample of n = 68 depressed patients 
was recruited within a European multicenter collaboration on 
depression and analysed at the IRCCS Fatebenefratelli Brescia. 
The study was approved by the local Ethic Committees of the 
Institutes. Diagnosis of depression was confirmed by clinical 
interviews using the Structured Clinical Interview for DSM-IV, 
and severity (and treatment response) was assessed using the 
MADRS at baseline and at week 12. The mean (SD) MADRS score 
at baseline was 29.5 (± 3.9); using the same criteria used in the 
GENDEP sample to classify responders and nonresponders, 66% 
(45 of 68) were defined as responders. At baseline, most patients 
were drug free; they then started pharmacological treatment with 
clinician-determined antidepressant drugs: 20 took an selective 
serotonin reuptake inhibitors (SSRI) (mostly escitalopram and 
paroxetine), 20 a serotonin and noradrenaline reuptake inhibitor 
(mostly duloxetine and venlafaxine), and 14 a tricyclic (mostly 
amitriptyline and desipramine). Participants were excluded if 
they were taking antipsychotics or mood stabilizers, or if they had 
a history of neurological or comorbid psychiatric disorders (Axis 
I or Axis II), substance abuse, or severe medical illness or head 
injury. Written informed consent was obtained from all partici-
pants, and the study was approved by the local ethics committee. 
Demographic and clinical features are summarized in Table 1.
Blood Sample Collection and RNA Isolation
In both clinical groups, blood sample collection for gene expres-
sion analyses in leukocytes was performed at baseline (before 
starting antidepressant treatment) using PaxGene tubes. After 
blood collection, PaxGene tubes were kept for 2 hours at room 
temperature and then stored at -20°C for 24 hours and then at 
-80°C until their processing. RNA isolation was performed using 
the PaxGene Blood RNA Kit (Qiagen) according to the manufac-
turer’s protocols. The RNA quantity was assessed by evaluation 
of the A260/280 and A260/230 ratios using a Nanodrop spec-
trometer (NanoDrop Technologies, Wilmington, DE), and RNA 
quality was determined using an Agilent Bioanalyzer (Agilent 
Technologies). RNA samples were then stored at -80°C until 
their processing for gene expression analyses.
Generation of Absolute mRNA Molecule Number 
through External Calibration Curves
After the initial multivariate logistic regression analysis (see 
Results below), which identified MIF and IL-1β as the strongest 
predictors of treatment response in the GENDEP sample, sub-
sequent quantification analyses concentrated on only these 2 
cytokines. We performed an absolute gene expression analyses 
to get absolute levels of cytokines mRNA expression, a novel 
approach that does not require normalization with “housekeep-
ing” genes and is more likely to be comparable across different 
laboratories because of the use of standard quantitation. cDNA 
clones for human MIF and IL-1β were available from Origene 
(MIF NM_002415 and NM_000576, 10ug). Purified plasmid clones 
were then quantified using the PicoGreen method. Knowing the 
copy numbers and the concentration of plasmid cDNA, the pre-
cise number of molecules added to real time-PCR runs can be 
calculated providing a standard for specific cDNA quantification. 
Oligonucleotides specific for MIF and IL-1β, as well as 3 house-
keeping genes (β-actin, β2-microglobulin [B2M], and GAPDH) 
were designed with Primer 3 software (http://www.bioinformat-
ics.nl/cgi-bin/primer3plus/primer3plus.cgi) and used in subse-
quent real time reactions. Primer and probes sequences were: 
for β-actin, FW primer: CACACGCAGCTCATTGTAGA, RW primer: 
GGCATGGGTCAGAAGGATT, probe: GAAAATCTGGCACCACACCT; 
for B2M, FW primer ATGCCTGCCGTGTGAACCATGT, RW 
primer: TCAACCCTCCATGATGCTGCT, probe: CACTGAATTCACC 
CCCACTGA; for GAPDH, FW primer TTCACACCCATGACGAACAT, 
RW primer: CGAGATCCCTCCAAAATCAA, probe: GCCAAAAGGGTC 
ATCATCTC; for IL-1β, FW primer GGAGAATGACCTGACCACCT, 
RW primer: GGAGGTGGAGAGCTTTCAGT, probe: ACGATGCACC 
TGTACGATCA; for MIF, FW primer CGCAGAACCGCTCCTACAG, 
RW primer: AGGCGAAGGTGGAGTTGTTC, probe: 
CCGGACAGGGTCTACATCAA. For each primer and probe set, we 
ran a standard curve whose slope was used to calculate the PCR 
efficiencies, which were EMIF = 2.0 and EIL-1β = 1.9. Real time PCR 
runs were performed in triplicate, with 1 μL of template (10 ng 
of RNA) unknown cDNA from patients, or 1 μL of clone cDNA (8 
dilution points ranging from 1e03 to 1e06), in a final volume of 
2.5 μL.
The standard curve was built up with external clones con-
taining MIF or IL-1β mRNA. Specifically, a known amount of 
plasmid was used to construct a calibration curve, and then 
unknown samples (mRNA from patients) were quantified as 
number of mRNA molecules (Li and Wang, 2000). After having 
checked for the efficiency of the assays, standard curves for MIF 
and IL-1β were run together (in the same reaction plate) with the 
mRNA samples of patients, and the threshold cycle (Ct) values of 
MIF or IL-1β for samples from patients were compared with the 
Ct values of the dilution points of the standard curve to get an 
absolute value of expression of each cytokine (total number of 
MIF or IL-1β mRNA molecules per nanogram total RNA) in each 
patient. In particular, a standard curve was obtained by plotting 
the natural log of the Ct against the natural log of the number 
of molecules.
To ensure that any differences in absolute levels of cytokines 
mRNA expression were not due to generic differences in the lev-
els of mRNA, we measured the mRNA levels of 3 housekeeping 
genes in both independent samples, and we then expressed the 
values in term of relative expression Ratio, with “responders” as 
reference group.
MIF and IL-1β Network Analysis
As MIF and IL-1β might be involved in different pathways, we 
constructed a protein-protein interaction network by using 
Table 1. Demographic and Clinical Information for the Two Samples of Depressed Patients
Age Gender (% Female) Baseline MADRS Responders (%)
GENDEP sample (n = 74) 38.3 ± 10.9 58.1% (31M/43F) 28.7 ± 4.2 69% (51/74)
Validation sample (n = 68) 39 ± 9.5 52.9% (32M/36F) 29.5 ± 3.9 66% (45/68)
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the Search Tool for the Retrieval of Interacting Genes/Proteins 
(STRING) Network Analyses software (http://string-db.org/) to 
identify the closest interacting genes and the main networks 
that are regulated.
Statistical Analyses
Preliminary descriptive analysis, based on Mann-Whitney non-
parametric test (for non-Gaussian distributions), was carried out 
to assess any significant differences in mRNA relative cytokines 
between the responder and nonresponder categories. Initially, a 
multiple logistic regression model was carried out in the GENDEP 
sample through the backward Wald method for the selection of 
the strongest predictors of treatment response using cytokines rel-
ative mRNA values of IL-1β, MIF, and TNF-α. Subsequently, univari-
ate logistic models were performed to evaluate the associations 
between selected biomarkers with treatment response. The abso-
lute values of the selected cytokines (numbers of molecules per 
nanogram total RNA) were then calculated, as described above. 
Subsequently, we used a linear discriminant analysis (LDA) to ana-
lyze the linear combination of the absolute values of the cytokines 
in relationship with treatment response to define a rule able to 
discriminate responders or nonresponders (Mc Lachlan, 2004). 
The resulting combination, named linear discriminant function 
(LDF), was then used as a linear classifier able to separate patients 
according to the scores of this function, indicating the probability 
of each individual of belonging to the responder or nonresponder-
classes based on cutoff values of MIF and IL-1β mRNA molecules. 
Finally, to validate these findings, we assessed the performance 
of the same cutoff values (numbers of molecules) on generating 
probability scores in the second validation sample. Positive and 
negative predictive values (PPV, NPV), specificity, and sensitivity 
were calculated in both samples for the probability of being a non-
responder. Statistical analyses were carried out with SPSS 21.0 and 
R language and environmental v.3.0.3. (R Development Core Team, 
2013). Statistical significance was set at P < .05.
Results
Baseline mRNA relative Expression of MIF and IL-1β, 
but Not TNF-α, Predicts Treatment Response in the 
GENDEP Sample
As mentioned above, we had previously found that nonresponders 
in the GENDEP sample had higher baseline mRNA relative expres-
sion levels of 3 proinflammatory cytokines, IL-1β, MIF, and TNF-α, 
compared with responders; these findings were present for both 
escitalopram and nortryptiline nonresponders (Cattaneo et  al., 
2013). In those analyses, we did not apply any variable selection 
procedure; however, we found that TNF-α had the lowest predict-
ing power (adjusted R2 = 0.19) compared with both IL-1β (adjusted 
R2 = 0.31) and MIF (adjusted R2 = 0.37) (Cattaneo et al., 2013).
In the present study, we detected the biomarkers that were 
more strongly associated with treatment response by using a 
multiple logistic regression model applying the backward Wald 
method for the variable selection, which automatically removes 
variables that do not add more significance to the model. We 
found that MIF and IL-1β were strongly associated with treat-
ment response: the odd ratios (ORs) of being a nonresponder vs 
being a responder (obtained by univariate logistic models) were 
OR = 1.32 (95% CI 1.04–1.70, P = .034) for MIF, and OR = 1.24 (95% CI 
1.02–1.54, P = .049) for IL-1β, with higher levels predicting lack of 
response. Moreover, the power of the model increased (with an 
R2 of Negelkerke index increasing from 0.86 to 0.95) when IL-1β 
was evaluated together with MIF in the same logistic regression 
model (OR = 1.44, P = .030). TNF-α, in contrast, did not signifi-
cantly increase the predictive power (P > .05) and was removed 
from the model by backward selection method. Of note, the ORs 
were similar when we analyzed separately the response pre-
diction to escitalopram (OR = 1.34, P = .029 for MIF, and OR = 1.29, 
P = .035 for IL-1β) and to nortriptyline (OR= 1.35, P = .038 for MIF, 
and OR=1.20, P = .045 for IL-1β), indicating that these cytokines 
predict treatment response to both antidepressants.
Baseline mRNA Absolute Expression of MIF and IL-1β 
Accurately Discriminate between Responders and 
Nonresponders at the Individual Level
We measured the absolute blood mRNA expression of MIF and 
IL-1β in the GENDEP sample in order to get absolute (and not rela-
tive) mRNA measurements. Overall, means ± SEM in the whole 
sample were 66.8 ± 3.5 x 106 for IL-1β and 130.2 ± 5.2 x 106 for 
MIF. Consistently with our previous findings using relative gene 
expression approach (Cattaneo et al., 2013), we found that the 
mean absolute number of molecules for MIF and IL-1β were sig-
nificantly higher in nonresponders compared with responders 
(mean ± SEM; IL-1β: 83.1 ± 4.8 x 106 in nonresponders vs 50.4 ± 2.1 
x 106 in responders, t = 11.7, DF = 72, P < .001; MIF: 102.5 x 106 ± 4.2 
in nonresponders vs 55.4 x 106 ± 1.9 in responders, t = 7.2, DF = 72, 
P < .001).
We then used an LDA to analyze the linear combination of 
the absolute values of MIF and IL-1β in relationship with treat-
ment response to define a rule able to discriminate between 
responders and nonresponders (Mc Lachlan, 2004). Specifically, 
we first used LDA to calculate the coefficients for each biomarker 
(resulting in 0.056 for MIF and 0.036 for IL-1β, respectively) and 
then used the LDF to calculate the probability of each individual 
of belonging to the responder or nonresponder classes based on 
cutoff values of MIF and IL-1β mRNA molecules (Table 2). The 
table shows the relative probability of being a responder (in 
green) or nonresponder (in red) based on the LDF and according 
to the quantitative chosen cutoff values. The top-left cells rep-
resent patients with the lowest levels of inflammation and the 
highest probability of being a responder, virtually equal to 100%; 
with increasing levels of either or both cytokines, the probability 
of being a responder decreases dramatically, with bottom-right 
cells being characterized by a probability of being a responder 
virtually equal to zero. Specifically, green (responder) indicates 
>73% probability of being a responder and <27% probability of 
being a nonresponder; red (nonresponder) indicates <32% prob-
ability of being a responder and >72% probability of being a 
nonresponder; and orange indicates intermediate values. Based 
on these criteria, this sample had n = 35 (47%) of subjects clas-
sified as responders (MIF ≤ 60 x 104 and IL-1β ≤ 85 x 104), n = 23 
(31%) of subjects classified as nonresponders (MIF > 95 x 104 and 
IL-1β > 50 x 104), and n = 16 (22%) of subjects classified as interme-
diates (MIF = 60 x 104 - 95 x 104 and IL-1β = 50 x 104 - 85 x 104).
We then calculated PPV, NPV, sensitivity, and specific-
ity for being a nonresponder using the specific cutoff values 
(MIF > 95 x 104 and IL-1β > 50 x 104; red cells in the table). 100% 
of those classified as nonresponders (n = 14) were true non-
responders (PPV = 100%), and all true responders (n = 51) were 
identified as responders (specificity = 100%). This is ideal in 
terms of clinical practice: using this approach, only true nonre-
sponder patients would be exposed to a more rapid or assertive 
antidepressant strategies (see also Discussion). Nine (39%) of 
nonresponders were not identified as such (NPV = 85%, sensitiv-
ity = 61%): in terms of clinical practice, they would continue to 
receive standard treatment.
We found no difference in the expression levels of the 3 
housekeeping genes in this sample; mean ± SEM in responders 
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vs nonresponders were: β-actin: 1.08 ± 0.7 vs 1.09 ± 0.6; B2M: 
1.11 ± 0.8 vs 1.11 ± 0.4; GAPDH: 1.03 ± 0.4 vs 1.09 ± 0.6 (all P > .05).
MIF and IL-1β mRNA Molecules as Predictors 
of Treatment Response Are Validated in an 
Independent Sample
We also measured the number of MIF and IL-1β mRNA mol-
ecules in the second independent sample of 68 depressed 
patients. Overall, the absolute RNA levels observed in this sec-
ond validation sample were similar to those observed in the first 
group (mean and SEM were 66.5 ± 3.4 x 106 for IL-1β and 74.8 ± 2.9 
x 106 for MIF). As a first validation, we found that, similarly to the 
GENDEP sample, nonresponders had higher numbers of MIF and 
IL-1β molecules compared with responders (mean ± SEM; IL-1β: 
78.5 ± 3.5 x 106 in nonresponders vs 54.4 ± 3.2 x 106 in responders, 
t = 9.8, DF = 50, P < .01; MIF: 94.3 ± 3.2 x 106 in nonresponders vs 
55.3 ± 2.7 x 106 in responders, t = 8.2, DF = 50, P < .001). The results 
remain the same also when analyzing separately responders 
and nonresponders to SSRI (P = .008 for IL-1β and P = .009 for MIF) 
or SNRI (P = .003 for IL-1β and P = .009 for MIF), replicating the 
evidence from the GENDEP sample that these cytokines predict 
treatment response to both antidepressants.
As reported in Table 3, we then used the second sample to 
validate our predictive model based on the absolute mRNA cut-
off values identified in the first sample. Indeed, we obtained 
probability scores for being responders/non-responders that 
were very similar to those obtained in the first sample (P > .05 
for all comparisons between probability scores), again, with top-
left cells representing patients with the lowest levels of inflam-
mation and the highest probability of being a responder, and 
bottom-right cells representing those with the highest levels of 
inflammation and the lowest probability of being a responder. 
Specifically, green (responder) indicates >82% probability of 
being a responder and <18% probability of being a nonre-
sponder; red (nonresponder) indicates <28% probability of being 
a responder and >72% probability of being a nonresponder; and 
orange indicate intermediate values. Based on these criteria, 
this sample had n =  29 (43%) of subjects classified as respond-
ers (MIF ≤ 60 x 104 and IL-1β ≤ 85 x 104), n =  13 (19%) of subjects 
classified as non-responders (that is, with MIF > 95 x 104 and 
IL-1β > 50 x 104), and n = 26 (38%) of subjects classified as interme-
diates (that is, MIF = 60 x 104 - 95 x 104 and IL-1β = 50 x 104 - 85 x 104). 
Similar to the GENDEP sample, 100% of those classified as non-
responders (n = 13) were true nonresponders (PPV = 100%), and 
all true responders (n = 45) were identified as responders (speci-
ficity = 100%). Ten (43%) of nonresponders were not identified as 
such (NPV = 82%, sensitivity = 56%).
Again, we found no difference in the expression levels of 
the three housekeeping genes in this sample; mean ± SEM 
in responders vs nonresponders were: β-actin: 1.09 ± 0.8 vs 
1.10 ± 0.7; B2M: 1.08 ± 0.5 vs 1.10 ± 0.7; GAPDH: 1.06 ± 0.5 vs. 
1.08 ± 0.7 (all P > .05).
MIF and IL-1β Network Analysis Identifies Different 
Molecular Targets
The network analysis showed that MIF and IL-1β were directly 
linked as reciprocal targets (data not shown), indicating that 
increased activation of one cytokine has downstream effects 
also on the other. However, the 2 cytokines connected to dif-
ferent and specific clusters of targets. As shown in Figure  1a, 
MIF did not show any interactions with other proinflammatory 
cytokines, and it interacted mainly with ubiquitin C via matrix 
metalloproteinase 9, which, in turn, is involved in the regulation 
of genes known to have an effect on neurogenesis, neuroplasti-
city, and cell proliferation, like Endothelial Growth Factor, Notch, 
and SMAD proteins (Anacker et al., 2013; Marschallinger et al., 
2014). On the contrary, the neighbor targets of IL-1β (Figure 1b) 
were mainly represented by proteins with inflammatory prop-
erties, including IL-6 and CRP, and by other molecules involved 
in the upstream or downstream regulation of the inflammatory 
signal, like Toll Like Receptors, Caspases (CASP), and nuclear 
factor kappa-light-chain-enhancer of activated B cells; inter-
estingly all of these partners are related to the inflammasome 
complex or are mediators of oxidative stress, and they are well 
known to cause neurodegenerative effects (Leemans et al., 2011; 
Radi et al., 2014).
Discussion
In this study we report that the absolute numbers of MIF and 
IL-1β mRNA molecules are both accurate and reliable predic-
tors of antidepressant response, identifying, for the first time, 
an mRNA-based biomarker approach that is independent from 
local experimental settings and does not require “relative” 
quantification using housekeeping genes. Of note, the predic-
tive power of these proinflammatory cytokines, and in particu-
lar the absolute values of mRNA molecules identified as the best 
cutoffs for prediction of nonresponse on an individual basis, 
Table 2. Cutoff Values of MIF and IL-1β Molecules and Probability Scores of Being a Responder or a Nonresponder in the First Sample of De-
pressed Patients (GENDEP Sample)
Number of molecules (IL-1β or 
MIF) per nanogram total RNA IL-1β ≤ 50 x 104 50 x 104 < IL-1β ≤ 85 x 104 IL-1β > 85 x 104
MIF ≤ 60 x 104 Responder probability >0.995 Responder probability >0.73 Responder probability >0.37
Nonresponder probability
<0.005
Nonresponder probability
<0.27
Nonresponder probability
<0.63
60 x 104 < MIF ≤ 95 x 104 Responder probability >0.32 Responder probability 0.008–0.995 Responder probability <0.73
Nonresponder probability
<0.68
Nonresponder probability
0.005–0.99
Nonresponder probability
>0.27
MIF > 95 x 104 Responder probability 0.03–0.93 Responder probability <0.32 Responder probability <0.008
Nonresponder probability
0.07–0.97
Nonresponder probability
>0.72
Nonresponder probability
>0.99
White columns on the right represent MIF cutoffs (in term of number of molecules) and white rows on the top represent IL-1β cutoffs (in term of number of 
 molecules); each cells or in green, orange, or red indicates the probability of being a responder or a nonresponder: green (responder) indicates >73% probability  
of being a responder and <27% probability of being a nonresponder; red (nonresponder) indicates <32% probability of being a responder and >72% probability of being 
a nonresponder; and orange indicate intermediate values.
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were independently replicated in two clinical samples: a ran-
domized trial that we had previously used to measure relative 
mRNA expression and to identify the top mRNA transcripts of 
interest (Cattaneo et al., 2013); and a naturalistic cohort that has 
been independently recruited for this study. Both samples dem-
onstrate identical PPV and specificity of 100% for nonrespond-
ers. This is the ideal scenario in clinical practice: patients with 
mRNA numbers above the suggested cutoffs (“red” in Tables 2 
and 3) could be directed toward early access to more assertive 
antidepressant strategies, including augmentation with other 
antidepressants or antiinflammatory drugs, while those with 
mRNA numbers below the suggested cutoffs could be directed 
toward standard care. Most importantly, this would allow a ther-
apeutically conservative approach, where no true responders 
would be exposed unnecessarily to more assertive pharmaco-
logical strategies.
Depressed patients who are resistant to conventional antide-
pressants have higher concentrations of inflammatory biomark-
ers in plasma or serum (Sluzewska et al., 1997; Lanquillon et al., 
2000; Fitzgerald et al., 2006), and successful antidepressant treat-
ment has been associated with a reduction in the levels of pro-
inflammatory cytokines (Abdel-Salam et  al., 2003; Roumestan 
et  al., 2007; Cattaneo et  al., 2013). As mentioned above, we 
conducted the first study showing that (relative) mRNA expres-
sion levels of IL-1β, MIF, and TNF-α are higher in nonresponders. 
Our findings have been corroborated by Belzeaux and colleagues 
(2012), who identified a combination of mRNA signatures of 
TNFα and IL-1β as best predictors of antidepressant response in 
a case study, and by Powell and colleagues (2013) in a separate 
study of a different GENDEP sample, who investigated the mRNA 
expression of 84 genes related to inflammation and found that 
nonresponders have significantly higher baseline mRNA levels 
of TNF and other TNF-target genes. Cytokine mRNA levels may 
also be involved in the genetic regulation of treatment response: 
for example, Uher et  al. (2010) have found, in yet another 
GENDEP sample, a single nucleotide polymorphism (rs1126757) 
in the IL-11 gene with suggestive genome-wide significance, 
and Powell et al. (2013) have found that only carriers of the IL-11 
A allele (who have a better response) show a significant reduc-
tion in IL-11 mRNA expression following citalopram. Together 
with the present findings showing accurate and reliable pre-
diction of antidepressant response by absolute mRNA levels in 
2 independent samples, all these studies show that peripheral 
blood mRNA analyses are one of the most promising approaches 
for biomarker discovery in mental health (Hepgul et al., 2013). 
This notion is supported by the fact that about 80% of genes 
Table  3. Cutoff Values of MIF and IL-1β Molecules and Probability Scores of Being a Responder or a Nonresponder in the Second 
Independent Sample of Depressed Patients
Number of Molecules (IL-1β or 
MIF)/ng Total RNA IL-1β ≤ 50 x 104 50 x 104 < IL-1β ≤ 85 x 104 IL-1β > 85 x 104
MIF ≤ 60 x 104 Responder probability >0.99 Responder probability >0.82 Responder probability >0.39
Nonresponder probability
<0.001
Nonresponder probability
<0.18
Nonresponder probability
<0.61
60 x 104 < MIF ≤ 95 x 104 Responder probability >0.28 Responder probability 0.001–0.99 Responder probability <0.82
Nonresponder probability
<0.72
Nonresponder probability
0.001–0.99
Nonresponder probability
>0.18
MIF > 95 x 104 Responder probability 0.007–0.97 Responder probability <0.28 Responder probability <0.001
Nonresponder probability
0.03–0.99
Nonresponder probability
>0.72
Nonresponder probability
>0.99
White columns on the right represent MIF cutoffs (in term of number of molecules) and white rows on the top represent IL-1β cutoffs (in term of number of 
 molecules); each cells or in green, orange, or red indicates the probability of being a responder or a nonresponder: green (responder) indicates >82% probability of be-
ing a responder and <18% probability of being a nonresponder; red (nonresponder) indicates <28%; probability of being a responder and >72% probability of being  
a nonresponder; and orange indicate intermediate values.
Figure 1. Representative interaction between Macrophage Migration Inhibitory Factor (MIF) (Figure 1a) or interleukin (IL)-1β (Figure 1b) and their neighbors’ targets, 
where nodes (genes) can be either colored (if they are directly linked to the input, in that case MIF) or white (nodes of a higher interaction/depth-this is not the case). 
Lines represent predicted functional edges of interaction between nodes, and they are represented with eight different colors according to the type of evidence and the 
predictive method used (neighborhood, gene fusion, co-occurrence, coexpression, experiments, databases, and textmining): green line, activation; red line,  inhibition; 
blue line, binding; light blue line, phenotype; violet, catalyzes; pink, posttranslational mechanism; black, reaction; yellow, coexpression (http://string-db.org).
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are coexpressed, and similarly modulated as mRNA levels, in 
peripheral blood cells and brain tissues (Sullivan et  al., 2006). 
Moreover, molecular mechanisms activated by early life stress, 
a well-known risk factor for antidepressant nonresponse (Nanni 
et al., 2012), produce similar epigenetic changes in human blood 
cells and human neuronal cells, leading to long-term dysregu-
lation of the stress hormone system and global changes in the 
function of immune cells as well as of brain areas associated 
with stress regulation (Klengel et al., 2013; Uher et al., 2014).
In our study, we find that MIF and IL-1β mRNA levels pre-
dict treatment response across antidepressants classes, that is, 
for both escitalopram and nortriptyline in the GENDEP samples 
as well as for both SSRIs and SNRIs in the naturalistic cohort. 
These findings may be perceived as in contrast with the recent 
paper by Uher et al. (2014) showing (in a larger, different GENDEP 
sample) that high levels of serum CRP predicted lack of treat-
ment response to the SSRI, escitalopram, but not to the tricy-
clic (and noradrenergic uptake inhibitor) nortriptyline. The 
authors explain this by speculating that antidepressants with 
a noradrenergic action may have antiinflammatory properties 
(Uher et al., 2014), and, in fact, we and others have found that 
noradrenergic or SNRI antidepressants have antiinflammatory 
properties in vitro (Horowitz et al., 2014). However, the antiin-
flammatory properties of SSRI drugs are also well known (Tynan 
et al., 2012; Al-Amin et al., 2013; Cattaneo et al., 2013). Our net-
work analysis may shed some light on this apparent discrep-
ancy, as CRP is only loosely connected with IL-1β (and it is not 
connected with MIF), indicating that subjects with high levels of 
CRP may be different from those with high levels of MIF or IL-1β; 
indeed CRP levels in the aforementioned paper predicted only 
around 11% of MADRS-based response, as opposed to 40% to 
50% of the variance explained by cytokines mRNA levels in our 
study (Cattaneo et  al., 2013). Moreover, because MIF and IL-1β 
are “neighbor targets,” it is possible that having high levels of 
either of these cytokines (i.e., above the top cutoff) is enough 
to activate downstream targets of both, thus affecting both the 
neurogenesis/neuroplasticity targets of MIF and the inflam-
masone/neurodegeneration targets of IL-1β. These widespread 
molecular abnormalities would likely inhibit the response to a 
wide range of antidepressants. Of note, taken together with the 
other GENDEP studies mentioned above by Uher et al. (2010) and 
Powell et al. (2013), our study and the study by Uher et al. (2014) 
all point to a prominent role of increased inflammation in the 
lack of antidepressant response in the GENDEP cohort. However, 
as these studies have been conducted in different and only par-
tially overlapping samples, it is difficult to determine if and how 
these genetic, serum, and mRNA biomarker cluster together.
High levels of inflammation can prevent response to anti-
depressants, because it can interfere with the same biologi-
cal processes that are crucial for antidepressant therapeutic 
action. For example, high levels of inflammation increase the 
expression and activation of monoamine transporters, reduce 
tryptophan availability, inhibit neuropeptide and growth factors 
involved in neuroplasticity, and interfere with the kynurenine 
pathways, leading in turn to a reduction in neurogenesis and 
glutamate dysfunction (Zunszain et al., 2012; Felger and Lotrich, 
2013). Of note, inflammation can be triggered by childhood 
trauma (Danese et al., 2007, 2008; Hepgul et al., 2013; Baumeister 
et al., 2015), which is in itself associated with poor antidepres-
sant response (Nanni et al., 2012); thus, it is possible to speculate 
that a cluster of individuals have both a history of childhood 
trauma and increased inflammation, eventually leading to lack 
of antidepressant response (Nemeroff et al., 2003; Nanni et al., 
2012; Coelho et al., 2014). However, it is also known that genetic 
variability in inflammatory genes, such as IL-6, IL-11, and TNF-
α, as well as in enzymes involved in the prostaglandins and 
kynurenine pathways, contributes to both the risk of depression 
and to antidepressant response (Bull et al., 2009; Dowlati et al., 
2010; Uher et al., 2010; Bufalino et al., 2013), thus suggesting that 
a different cluster of individuals expresses high levels of inflam-
mation and lack of treatment response through a predominantly 
genetic path. Indeed, it is possible that the better accuracy and 
validity of mRNA gene expression as biomarkers of treatment 
response are due to the ability of these molecules to integrate 
genomic variability and environmental effects. Importantly, 
inflammatory genes could represent not only biomarkers pre-
dicting lack of antidepressant response but also novel targets 
for antidepressant therapies, and indeed clinical trial have been 
conducted to test the efficacy of antiinflammatory drugs. Müller 
et  al. (2006) was the first to conduct a randomized controlled 
clinical trial to evaluate the efficacy of celecoxib added to anti-
depressant drugs and reported improved antidepressant effects. 
Subsequent studies confirmed these findings (Akhondzadeh 
et al., 2009; Hashemian et al., 2011; Abbasi et al., 2012). Moreover, 
Raison and colleagues (2013) have recently reported that a 
specific antagonist of TNFα improves depressive symptoms in 
patients with high inflammation at baseline. No clinical trials 
have been conducted with drugs able to inhibit MIF or IL-1β; 
however, there are promising data in animals that IL-1β recep-
tor antagonism prevents long-term cognitive impairment 
and memory deficits, which are clinical features observed in 
depressed patients (Barichello et al., 2015).
The targets identified by the network analyses of MIF and 
IL-1β shed some interesting light on the putative molecu-
lar mechanisms underlying their predictive effects. MIF pro-
motes the expression and function of multiple cytokines and 
chemokines, including TNF-alpha, IL-6, CXCL1, and CCL2 
(Gregory et  al., 2006; Toh et  al., 2006; Fan et  al., 2011; Santos 
et  al., 2011). However, MIF also plays a role as a physiological 
counter-regulator of glucocorticoid antiinflammatory action 
(Leech et  al., 2000; Aeberli et  al., 2006) by regulating glucocor-
ticoid-induced leucine zipper, which in turn not only has anti-
inflammatory functions but also is involved in the effects of 
stress on neurogenesis (Anacker et  al., 2013). Finally, MIF also 
interacts with genes involved in neurogenesis, neuroplasticity, 
and cell proliferation, like Endothelial Growth Factor, Notch, and 
SMAD proteins (Anacker et al., 2013; Marschallinger et al., 2014). 
Indeed, MIF has been shown to promote neuroplasticity and 
neuroprotective processes under physiological conditions, but it 
can also increase the production of proinflammatory cytokines 
under conditions of stress. Moreover, MIF is modulated by gluco-
corticoids, and high, antiinflammatory doses of glucocorticoids 
inhibit MIF secretion; however, during pathological conditions 
characterized by glucocorticoid resistance, such as depression, 
it is conceivable that levels of MIF are increased (Bloom et al., 
2014). In contrast, IL-1β contributes to the activation of other 
cytokines (IL-18, IL-6) and mediators of oxidative stress, like 
CASP1, CASP9, and Nitric oxide synthase 2, related to the inflam-
masome complex, also comprising the Nod-like Receptor, the 
precursor pro-caspase-1, and the adaptor ASC. Interestingly an 
overactivation of the inflammasome in peripheral blood cells of 
depressed patients has been recently demonstrated, providing 
support to its putative role in the pathogenesis of depression 
and its treatment (Alcocer-Gomez and Cordero, 2014). We would 
advocate that any of these pathways might represent a target 
for novel antidepressant therapies.
The finding that markers of peripheral inflammation can pre-
dict the response to an antidepressant can be interpreted as an 
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example of a peripheral correlate of central (immune) alterations. 
Indeed, increased neuro-inflammation has been reported in the 
brain of patients with depression; for example, postmortem studies 
have found an increased proportion of primed microglia and higher 
mRNA levels of several chemokines involved in the recruitment of 
monocytes (Torres-Platas et al., 2014); and a recent neuroimaging 
study has found increased microglia activation (translocator pro-
tein density) using positron emission tomography (Setiawan, et al., 
2015). Indeed, it has recently been proposed that microglial activa-
tion in psychiatric disorders could not only contribute to the brain 
pathology but also influence treatment response (Reus et al., 2015). 
It is also, however, important to highlight that readily available, 
blood-based peripheral biomarkers are relevant in psychiatry even 
if they do not directly reflect brain-based mechanisms when they 
reliably predict important clinical features such as risk, vulnerabil-
ity, outcome, and treatment response.
The findings of the present study need to be interpreted in 
the light of important limitations. First, although we have vali-
dated our results in 2 independent samples, the sample size is 
relatively small, and therefore these findings should be repli-
cated in larger datasets. Indeed, we have assessed “response” 
rather than “remission,” as the latter would have led to even 
smaller groups available for the analyses. Second, the identified 
biomarkers predict the response to antidepressants in general 
and are not specific to one or the other of the antidepressant 
classes; therefore, they cannot be used to guide the choice of 
antidepressants but rather to identify patients that may benefit 
from an early access to adjuvant therapies. Third, these find-
ings may be relevant only to patients that, as in our samples, 
show no historical evidence of chronicity or of treatment resist-
ance to multiple antidepressants, although we would argue that 
this is indeed the kind of patients that would benefit most from 
our proposed personalized approach of early access to assertive 
antidepressant strategies based on the biomarkers profile.
In summary, here we provide evidence that the measure-
ments of the number of MIF and IL-1β mRNA molecules, which is 
an absolute and thus reliable quantitation that could be adopted 
across laboratories, may help the clinicians in the prediction of 
antidepressant response, so that patients with mRNA numbers 
above the suggested cutoffs (“red”) could be directed toward 
early access to more rapid escalation of assertive antidepressant 
strategies. However, randomized controlled trials testing the 
use of biomarkers vs treatment as usual need to be conducted 
in order to deliver clear guidelines, especially considering the 
increased risk of adverse effects when combining conventional 
antidepressants with antiinflammatories (Andrade et al., 2010).
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